Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / DCC

DCC

Basics

Aliases:
This biomarker is also known as:
  • CRCR1,
  • immunoglobulin superfamily DCC subclass member 1,
  • Colorectal cancer suppressor,
  • tumor suppressor protein DCC,
  • IGDCC1,
  • deleted in colorectal carcinoma,
  • deleted in colorectal cancer protein,
  • Immunoglobulin superfamily DCC subclass member 1,
  • colorectal cancer suppressor,
  • immunoglobulin superfamily, DCC subclass, member 1,
  • CRC18,
  • Tumor suppressor protein DCC,
  • colorectal tumor suppressor,
  • netrin receptor DCC,

View in BioMuta

Description…

DCC is a receptor for netrin 1, which is required for axon guidance. DCC is a transmembrane protein and a member of the immunoglobulin superfamily of cell adhesion molecules. It mediates axon attraction of neuronal growth cones in the developing nervous system upon ligand binding. The cytoplasmic tail of DCC interacts with the tyrosine kinases Src and focal adhesion kinase (FAK, also known as PTK2) to mediate axon attraction. The protein partially localizes to lipid rafts, and induces apoptosis in the absence of ligand. The protein functions as a tumor suppressor, and is frequently mutated or downregulated in colorectal cancer and esophageal carcinoma.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: DCC

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Head & neck, NOS

Attributes

Phase: One
QA State: Curated

Overview

No additional data available.

Performance Comment

DCC is one of eight genes on a panel of differentially methylated genes from normal and OSCC clinical samples from patients with heterogenous risk profiles chosen for further validation. The eight genes are: HOXA9, NID2, GATA4, KIF1A, EDNRB, MCAM, DCC, and CALCA.

Lung

Attributes

Phase: Two
QA State: Under Review

Overview

Performance Comment

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.